Pharma & Healthcare
Global Drugs for Vulvovaginal Candidiasis Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 12, 25
- ID: 307051
- Pages: 123
- Figures: 126
- Views: 1
In 2024, the global market size of Drugs for Vulvovaginal Candidiasis was estimated to be worth US$ 841 million and is forecast to reach approximately US$ 932 million by 2031 with a CAGR of 1.5% during the forecast period 2025-2031.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world"s largest market, with a market share of about 45%, followed by North America with nearly 20%
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis.
The Drugs for Vulvovaginal Candidiasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Vulvovaginal Candidiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Vulvovaginal Candidiasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Segment by Application
Hospital & Clinic
Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Drugs for Vulvovaginal Candidiasis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Vulvovaginal Candidiasis sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world"s largest market, with a market share of about 45%, followed by North America with nearly 20%
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis.
The Drugs for Vulvovaginal Candidiasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Vulvovaginal Candidiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Vulvovaginal Candidiasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Segment by Application
Hospital & Clinic
Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Drugs for Vulvovaginal Candidiasis in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Vulvovaginal Candidiasis sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
1 Study Coverage
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Market by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
2.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2020-2031
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales 2020-2031
2.2 Drugs for Vulvovaginal Candidiasis Market Size by Region: 2024 Versus 2031
2.3 Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2031)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2020-2025
2.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2026-2031)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2020-2031)
2.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2020-2025
2.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2026-2031)
2.4.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2031)
3.1.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020-2031)
3.1.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2031)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2031)
3.1.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2031)
3.1.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2020-2031)
3.1.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2031)
3.2.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020-2031)
3.2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2031)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2031)
3.2.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2031)
3.2.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2020-2031)
3.2.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Cream of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application
3.3.2 Pessary of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application
3.3.3 Other of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application
4 Global Drugs for Vulvovaginal Candidiasis by Manufacturers
4.1 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Sales (2020-2025)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2020-2025)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (2020-2025)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2020-2025)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2020-2025)
4.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Drugs for Vulvovaginal Candidiasis Manufacturers Covered: Ranking by Revenue
4.4.2 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Product Type
4.5.1 Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
4.5.3 Manufacturers Drugs for Vulvovaginal Candidiasis Product Type and Application
4.5.4 Cream Market Sales of Drugs for Vulvovaginal Candidiasis by Manufacturer
4.5.5 Pessary Market Sales of Drugs for Vulvovaginal Candidiasis by Manufacturer
4.5.6 Other Market Sales of Drugs for Vulvovaginal Candidiasis by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bayer
5.1.1 Bayer Company Information
5.1.2 Bayer Description, Business Overview
5.1.3 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
5.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Bayer Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.1.6 Bayer Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.1.7 Bayer Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.1.8 Bayer Recent Developments
5.2 Perrigo
5.2.1 Perrigo Company Information
5.2.2 Perrigo Description, Business Overview
5.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
5.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Perrigo Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.2.6 Perrigo Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.2.7 Perrigo Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.2.8 Perrigo Recent Developments
5.3 J & J
5.3.1 J & J Company Information
5.3.2 J & J Description, Business Overview
5.3.3 J & J Drugs for Vulvovaginal Candidiasis Products Offered
5.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.3.5 J & J Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.3.6 J & J Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.3.7 J & J Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.3.8 J & J Recent Developments
5.4 Pfizer
5.4.1 Pfizer Company Information
5.4.2 Pfizer Description, Business Overview
5.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
5.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Pfizer Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.4.6 Pfizer Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.4.7 Pfizer Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.4.8 Pfizer Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Company Information
5.5.2 Bristol-Myers Squibb Description, Business Overview
5.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
5.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.5.6 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.5.7 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.5.8 Bristol-Myers Squibb Recent Developments
5.6 Effik
5.6.1 Effik Company Information
5.6.2 Effik Description, Business Overview
5.6.3 Effik Drugs for Vulvovaginal Candidiasis Products Offered
5.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Effik Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.6.6 Effik Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.6.7 Effik Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.6.8 Effik Recent Developments
5.7 Teva
5.7.1 Teva Company Information
5.7.2 Teva Description, Business Overview
5.7.3 Teva Drugs for Vulvovaginal Candidiasis Products Offered
5.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Teva Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.7.6 Teva Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.7.7 Teva Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.7.8 Teva Recent Developments
5.8 Sanofi
5.8.1 Sanofi Company Information
5.8.2 Sanofi Description, Business Overview
5.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
5.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.8.5 Sanofi Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.8.6 Sanofi Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.8.7 Sanofi Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.8.8 Sanofi Recent Developments
5.9 Cisen Pharmaceutical
5.9.1 Cisen Pharmaceutical Company Information
5.9.2 Cisen Pharmaceutical Description, Business Overview
5.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
5.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.9.5 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.9.6 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.9.7 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.9.8 Cisen Pharmaceutical Recent Developments
5.10 Kingyork Group
5.10.1 Kingyork Group Company Information
5.10.2 Kingyork Group Description, Business Overview
5.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
5.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.10.6 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.10.7 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.10.8 Kingyork Group Recent Developments
6 North America
6.1 North America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
6.2 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
6.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
6.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
6.3 North America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
6.4 North America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region
7.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2031)
7.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2031)
7.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
7.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
8 Europe
8.1 Europe Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
8.2 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
8.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
8.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
8.3 Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
8.4 Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
9.2 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
9.2.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
9.2.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
9.3 Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
9.4 Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
10.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
10.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
10.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
10.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Drugs for Vulvovaginal Candidiasis Supply Chain Analysis
11.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
11.3 Drugs for Vulvovaginal Candidiasis Clients Analysis
11.4 Drugs for Vulvovaginal Candidiasis Sales Channel and Sales Model Analysis
11.4.1 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Drugs for Vulvovaginal Candidiasis Distributors
12 Drugs for Vulvovaginal Candidiasis Market Dynamics
12.1 Drugs for Vulvovaginal Candidiasis Industry Trends
12.2 Drugs for Vulvovaginal Candidiasis Market Drivers
12.3 Drugs for Vulvovaginal Candidiasis Market Challenges
12.4 Drugs for Vulvovaginal Candidiasis Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Market by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts
2.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2020-2031
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales 2020-2031
2.2 Drugs for Vulvovaginal Candidiasis Market Size by Region: 2024 Versus 2031
2.3 Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2031)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2020-2025
2.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2026-2031)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2020-2031)
2.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2020-2025
2.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2026-2031)
2.4.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2031)
3.1.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020-2031)
3.1.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2031)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2031)
3.1.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2031)
3.1.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2020-2031)
3.1.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2031)
3.2.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020-2031)
3.2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2031)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2031)
3.2.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2031)
3.2.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2020-2031)
3.2.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Cream of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application
3.3.2 Pessary of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application
3.3.3 Other of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application
4 Global Drugs for Vulvovaginal Candidiasis by Manufacturers
4.1 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Sales (2020-2025)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2020-2025)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (2020-2025)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2020-2025)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2020-2025)
4.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Drugs for Vulvovaginal Candidiasis Manufacturers Covered: Ranking by Revenue
4.4.2 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Product Type
4.5.1 Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
4.5.3 Manufacturers Drugs for Vulvovaginal Candidiasis Product Type and Application
4.5.4 Cream Market Sales of Drugs for Vulvovaginal Candidiasis by Manufacturer
4.5.5 Pessary Market Sales of Drugs for Vulvovaginal Candidiasis by Manufacturer
4.5.6 Other Market Sales of Drugs for Vulvovaginal Candidiasis by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bayer
5.1.1 Bayer Company Information
5.1.2 Bayer Description, Business Overview
5.1.3 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
5.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Bayer Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.1.6 Bayer Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.1.7 Bayer Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.1.8 Bayer Recent Developments
5.2 Perrigo
5.2.1 Perrigo Company Information
5.2.2 Perrigo Description, Business Overview
5.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
5.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Perrigo Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.2.6 Perrigo Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.2.7 Perrigo Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.2.8 Perrigo Recent Developments
5.3 J & J
5.3.1 J & J Company Information
5.3.2 J & J Description, Business Overview
5.3.3 J & J Drugs for Vulvovaginal Candidiasis Products Offered
5.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.3.5 J & J Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.3.6 J & J Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.3.7 J & J Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.3.8 J & J Recent Developments
5.4 Pfizer
5.4.1 Pfizer Company Information
5.4.2 Pfizer Description, Business Overview
5.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
5.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Pfizer Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.4.6 Pfizer Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.4.7 Pfizer Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.4.8 Pfizer Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Company Information
5.5.2 Bristol-Myers Squibb Description, Business Overview
5.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
5.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.5.6 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.5.7 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.5.8 Bristol-Myers Squibb Recent Developments
5.6 Effik
5.6.1 Effik Company Information
5.6.2 Effik Description, Business Overview
5.6.3 Effik Drugs for Vulvovaginal Candidiasis Products Offered
5.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Effik Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.6.6 Effik Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.6.7 Effik Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.6.8 Effik Recent Developments
5.7 Teva
5.7.1 Teva Company Information
5.7.2 Teva Description, Business Overview
5.7.3 Teva Drugs for Vulvovaginal Candidiasis Products Offered
5.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Teva Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.7.6 Teva Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.7.7 Teva Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.7.8 Teva Recent Developments
5.8 Sanofi
5.8.1 Sanofi Company Information
5.8.2 Sanofi Description, Business Overview
5.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
5.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.8.5 Sanofi Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.8.6 Sanofi Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.8.7 Sanofi Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.8.8 Sanofi Recent Developments
5.9 Cisen Pharmaceutical
5.9.1 Cisen Pharmaceutical Company Information
5.9.2 Cisen Pharmaceutical Description, Business Overview
5.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
5.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.9.5 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.9.6 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.9.7 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.9.8 Cisen Pharmaceutical Recent Developments
5.10 Kingyork Group
5.10.1 Kingyork Group Company Information
5.10.2 Kingyork Group Description, Business Overview
5.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
5.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales by Product in 2024
5.10.6 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales by Application in 2024
5.10.7 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales by Geographic Area in 2024
5.10.8 Kingyork Group Recent Developments
6 North America
6.1 North America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
6.2 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
6.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
6.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
6.3 North America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
6.4 North America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region
7.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2031)
7.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2031)
7.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
7.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
8 Europe
8.1 Europe Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
8.2 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
8.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
8.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
8.3 Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
8.4 Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
9.2 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
9.2.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
9.2.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
9.3 Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
9.4 Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
10.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2031)
10.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2031)
10.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025)
10.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Drugs for Vulvovaginal Candidiasis Supply Chain Analysis
11.2 Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
11.3 Drugs for Vulvovaginal Candidiasis Clients Analysis
11.4 Drugs for Vulvovaginal Candidiasis Sales Channel and Sales Model Analysis
11.4.1 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Drugs for Vulvovaginal Candidiasis Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Drugs for Vulvovaginal Candidiasis Distributors
12 Drugs for Vulvovaginal Candidiasis Market Dynamics
12.1 Drugs for Vulvovaginal Candidiasis Industry Trends
12.2 Drugs for Vulvovaginal Candidiasis Market Drivers
12.3 Drugs for Vulvovaginal Candidiasis Market Challenges
12.4 Drugs for Vulvovaginal Candidiasis Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Drugs for Vulvovaginal Candidiasis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2025) & (K Units)
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer (2020-2025)
Table 18. Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2020-2025) & (USD/Unit)
Table 21. Ranking of Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
Table 24. Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
Table 26. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Bayer Company Information
Table 29. Bayer Description and Business Overview
Table 30. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 31. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 32. Bayer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 33. Bayer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 34. Bayer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 35. Bayer Recent Developments
Table 36. Perrigo Company Information
Table 37. Perrigo Description and Business Overview
Table 38. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 39. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 40. Perrigo Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 41. Perrigo Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 42. Perrigo Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 43. Perrigo Recent Developments
Table 44. J & J Company Information
Table 45. J & J Description and Business Overview
Table 46. J & J Drugs for Vulvovaginal Candidiasis Product
Table 47. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 48. J & J Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 49. J & J Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 50. J & J Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 51. J & J Recent Developments
Table 52. Pfizer Company Information
Table 53. Pfizer Description and Business Overview
Table 54. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 55. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 56. Pfizer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 57. Pfizer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 58. Pfizer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 59. Pfizer Recent Developments
Table 60. Bristol-Myers Squibb Company Information
Table 61. Bristol-Myers Squibb Description and Business Overview
Table 62. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 63. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 64. Bristol-Myers Squibb Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 65. Bristol-Myers Squibb Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 66. Bristol-Myers Squibb Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 67. Bristol-Myers Squibb Recent Developments
Table 68. Effik Company Information
Table 69. Effik Description and Business Overview
Table 70. Effik Drugs for Vulvovaginal Candidiasis Product
Table 71. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 72. Effik Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 73. Effik Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 74. Effik Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 75. Effik Recent Developments
Table 76. Teva Company Information
Table 77. Teva Description and Business Overview
Table 78. Teva Drugs for Vulvovaginal Candidiasis Product
Table 79. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Teva Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 81. Teva Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 82. Teva Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 83. Teva Recent Developments
Table 84. Sanofi Company Information
Table 85. Sanofi Description and Business Overview
Table 86. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 87. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Sanofi Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 89. Sanofi Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 90. Sanofi Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 91. Sanofi Recent Developments
Table 92. Cisen Pharmaceutical Company Information
Table 93. Cisen Pharmaceutical Description and Business Overview
Table 94. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 95. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Cisen Pharmaceutical Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 97. Cisen Pharmaceutical Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 98. Cisen Pharmaceutical Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 99. Cisen Pharmaceutical Recent Developments
Table 100. Kingyork Group Company Information
Table 101. Kingyork Group Description and Business Overview
Table 102. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 103. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. Kingyork Group Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 105. Kingyork Group Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 106. Kingyork Group Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 107. Kingyork Group Recent Developments
Table 108. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 109. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 110. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 111. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 112. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 113. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 114. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2025) & (K Units)
Table 115. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2026-2031) & (K Units)
Table 116. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2025) & (US$ Million)
Table 117. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2026-2031) & (US$ Million)
Table 118. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 119. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 120. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 121. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 122. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 123. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 124. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 125. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 126. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 127. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 128. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 129. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 130. Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 131. Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 132. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 133. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 134. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 135. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 136. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 137. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 138. Drugs for Vulvovaginal Candidiasis Key Raw Materials, Industry Status and Trend
Table 139. Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
Table 140. Drugs for Vulvovaginal Candidiasis Clients Status and Trend
Table 141. Drugs for Vulvovaginal Candidiasis Typical Clients
Table 142. Drugs for Vulvovaginal Candidiasis Distributors
Table 143. Drugs for Vulvovaginal Candidiasis Market Trends
Table 144. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 145. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 146. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2024 & 2031
Figure 4. Cream Product Picture
Figure 5. Pessary Product Picture
Figure 6. Other Product Picture
Figure 7. Global Drugs for Vulvovaginal Candidiasis Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2024 & 2031
Figure 9. Hospital & Clinic
Figure 10. Pharmacy
Figure 11. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 12. Global Drugs for Vulvovaginal Candidiasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Drugs for Vulvovaginal Candidiasis Market Size 2020-2031 (US$ Million)
Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales 2020-2031 (K Units)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2020-2031)
Figure 16. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
Figure 17. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2020-2031)
Figure 18. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2020-2031)
Figure 19. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
Figure 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2020-2031)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2020-2031)
Figure 22. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
Figure 23. Cream of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2024 VS 2031
Figure 24. Pessary of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2024 VS 2031
Figure 25. Other of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2024 VS 2031
Figure 26. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer in 2024
Figure 27. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. Cream Market Sales Proportion by Manufacturer in 2024
Figure 29. Pessary Market Sales Proportion by Manufacturer in 2024
Figure 30. Other Market Sales Proportion by Manufacturer in 2024
Figure 31. North America Drugs for Vulvovaginal Candidiasis Revenue 2020-2031 (US$ Million)
Figure 32. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 33. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 34. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue 2020-2031 (US$ Million)
Figure 35. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2020-2031)
Figure 36. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
Figure 37. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 38. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 39. Europe Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 41. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 42. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 43. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 44. Latin America Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 46. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2025)
Figure 47. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 48. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 49. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2020-2031 (US$ Million)
Figure 50. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 52. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 53. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 54. Drugs for Vulvovaginal Candidiasis Supply Chain (Upstream and Downstream Market)
Figure 55. Global Production Market Share of Drugs for Vulvovaginal Candidiasis Raw Materials by Region in 2024
Figure 56. Drugs for Vulvovaginal Candidiasis Distribution Channels
Figure 57. Global Drugs for Vulvovaginal Candidiasis Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 58. Global Drugs for Vulvovaginal Candidiasis Percentage 2020-2031: Online Sales VS Offline Sales
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Drugs for Vulvovaginal Candidiasis Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2025) & (K Units)
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer (2020-2025)
Table 18. Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2020-2025) & (USD/Unit)
Table 21. Ranking of Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
Table 24. Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
Table 26. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Bayer Company Information
Table 29. Bayer Description and Business Overview
Table 30. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 31. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 32. Bayer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 33. Bayer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 34. Bayer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 35. Bayer Recent Developments
Table 36. Perrigo Company Information
Table 37. Perrigo Description and Business Overview
Table 38. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 39. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 40. Perrigo Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 41. Perrigo Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 42. Perrigo Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 43. Perrigo Recent Developments
Table 44. J & J Company Information
Table 45. J & J Description and Business Overview
Table 46. J & J Drugs for Vulvovaginal Candidiasis Product
Table 47. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 48. J & J Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 49. J & J Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 50. J & J Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 51. J & J Recent Developments
Table 52. Pfizer Company Information
Table 53. Pfizer Description and Business Overview
Table 54. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 55. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 56. Pfizer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 57. Pfizer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 58. Pfizer Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 59. Pfizer Recent Developments
Table 60. Bristol-Myers Squibb Company Information
Table 61. Bristol-Myers Squibb Description and Business Overview
Table 62. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 63. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 64. Bristol-Myers Squibb Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 65. Bristol-Myers Squibb Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 66. Bristol-Myers Squibb Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 67. Bristol-Myers Squibb Recent Developments
Table 68. Effik Company Information
Table 69. Effik Description and Business Overview
Table 70. Effik Drugs for Vulvovaginal Candidiasis Product
Table 71. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 72. Effik Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 73. Effik Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 74. Effik Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 75. Effik Recent Developments
Table 76. Teva Company Information
Table 77. Teva Description and Business Overview
Table 78. Teva Drugs for Vulvovaginal Candidiasis Product
Table 79. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Teva Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 81. Teva Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 82. Teva Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 83. Teva Recent Developments
Table 84. Sanofi Company Information
Table 85. Sanofi Description and Business Overview
Table 86. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 87. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Sanofi Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 89. Sanofi Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 90. Sanofi Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 91. Sanofi Recent Developments
Table 92. Cisen Pharmaceutical Company Information
Table 93. Cisen Pharmaceutical Description and Business Overview
Table 94. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 95. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Cisen Pharmaceutical Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 97. Cisen Pharmaceutical Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 98. Cisen Pharmaceutical Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 99. Cisen Pharmaceutical Recent Developments
Table 100. Kingyork Group Company Information
Table 101. Kingyork Group Description and Business Overview
Table 102. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 103. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. Kingyork Group Sales Proportion of Drugs for Vulvovaginal Candidiasis by Product in 2024
Table 105. Kingyork Group Sales Proportion of Drugs for Vulvovaginal Candidiasis by Application in 2024
Table 106. Kingyork Group Sales Proportion of Drugs for Vulvovaginal Candidiasis by Geographic Area in 2024
Table 107. Kingyork Group Recent Developments
Table 108. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 109. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 110. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 111. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 112. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 113. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 114. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2020-2025) & (K Units)
Table 115. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2026-2031) & (K Units)
Table 116. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2020-2025) & (US$ Million)
Table 117. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2026-2031) & (US$ Million)
Table 118. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 119. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 120. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 121. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 122. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 123. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 124. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 125. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 126. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 127. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 128. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 129. Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 130. Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 131. Latin America Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 132. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2020-2025) & (K Units)
Table 133. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2026-2031) & (K Units)
Table 134. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2020-2025) & (US$ Million)
Table 135. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2026-2031) & (US$ Million)
Table 136. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2020-2025) & (K Units)
Table 137. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2020-2025) & (K Units)
Table 138. Drugs for Vulvovaginal Candidiasis Key Raw Materials, Industry Status and Trend
Table 139. Drugs for Vulvovaginal Candidiasis Key Raw Materials and Upstream Suppliers
Table 140. Drugs for Vulvovaginal Candidiasis Clients Status and Trend
Table 141. Drugs for Vulvovaginal Candidiasis Typical Clients
Table 142. Drugs for Vulvovaginal Candidiasis Distributors
Table 143. Drugs for Vulvovaginal Candidiasis Market Trends
Table 144. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 145. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 146. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 150. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2024 & 2031
Figure 4. Cream Product Picture
Figure 5. Pessary Product Picture
Figure 6. Other Product Picture
Figure 7. Global Drugs for Vulvovaginal Candidiasis Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2024 & 2031
Figure 9. Hospital & Clinic
Figure 10. Pharmacy
Figure 11. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 12. Global Drugs for Vulvovaginal Candidiasis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Drugs for Vulvovaginal Candidiasis Market Size 2020-2031 (US$ Million)
Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales 2020-2031 (K Units)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2020-2031)
Figure 16. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
Figure 17. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2020-2031)
Figure 18. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2020-2031)
Figure 19. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
Figure 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2020-2031)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2020-2031)
Figure 22. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
Figure 23. Cream of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2024 VS 2031
Figure 24. Pessary of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2024 VS 2031
Figure 25. Other of Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application, 2024 VS 2031
Figure 26. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer in 2024
Figure 27. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. Cream Market Sales Proportion by Manufacturer in 2024
Figure 29. Pessary Market Sales Proportion by Manufacturer in 2024
Figure 30. Other Market Sales Proportion by Manufacturer in 2024
Figure 31. North America Drugs for Vulvovaginal Candidiasis Revenue 2020-2031 (US$ Million)
Figure 32. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 33. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 34. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue 2020-2031 (US$ Million)
Figure 35. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2020-2031)
Figure 36. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2020-2031)
Figure 37. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 38. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 39. Europe Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 41. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 42. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 43. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 44. Latin America Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 46. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2025)
Figure 47. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 48. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 49. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2020-2031 (US$ Million)
Figure 50. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2020-2031)
Figure 52. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2020-2025)
Figure 53. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2020-2025)
Figure 54. Drugs for Vulvovaginal Candidiasis Supply Chain (Upstream and Downstream Market)
Figure 55. Global Production Market Share of Drugs for Vulvovaginal Candidiasis Raw Materials by Region in 2024
Figure 56. Drugs for Vulvovaginal Candidiasis Distribution Channels
Figure 57. Global Drugs for Vulvovaginal Candidiasis Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 58. Global Drugs for Vulvovaginal Candidiasis Percentage 2020-2031: Online Sales VS Offline Sales
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Medical Waste Fluid Solidifier Market Research Report 2025
Jun 12, 25
Global Metalized Bubble Material Market Research Report 2025
Jun 12, 25
Global 70% Isopropyl Rubbing Alcohol Market Research Report 2025
Jun 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232